Sunosi (solriamfetol) — Point32Health

excessive daytime sleepiness associated with narcolepsy

Initial criteria

Patient age ≥ 18 years
Prescribed by or in consultation with a neurologist or sleep specialist
For narcolepsy: documented diagnosis of excessive daytime sleepiness associated with narcolepsy AND EITHER (trial and failure, inadequate response, intolerance, or contraindication to modafinil OR armodafinil AND to one stimulant medication) OR (new to plan and stable on Sunosi ≥ 2 months prior to enrollment, excluding samples)
For obstructive sleep apnea: documented diagnosis of excessive daytime sleepiness associated with obstructive sleep apnea AND EITHER (trial and failure, inadequate response, intolerance, or contraindication to modafinil OR armodafinil AND documentation that the underlying airway obstruction is being treated concurrently) OR (new to plan and stable on Sunosi ≥ 2 months prior to enrollment, excluding samples, AND documentation of concurrent airway obstruction treatment)

Documentation that patient experienced improvement from baseline based on reduction in daytime sleepiness
For obstructive sleep apnea, documentation that patient is adherent to treatment(s) for the underlying airway obstruction (e.g., continuous positive airway pressure [CPAP])

12 months